DRTG(SH:600329)2025-10-30 09:15Financial Performance - The company's operating revenue for the third quarter was CNY 1,019,342,255.45, a decrease of 38.08% year-on-year[4] - Total profit for the quarter reached CNY 253,188,070.04, an increase of 44.05% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 224,559,220.11, reflecting a year-on-year increase of 53.66%[4] - Basic earnings per share for the quarter were CNY 0.30, an increase of 57.89% compared to the same period last year[5] - Total profit for the year-to-date increased by 172.92%, primarily due to the sale of a 12% stake in a joint venture, generating a disposal gain of 1.54 billion RMB after tax[10] - Net profit for the first three quarters of 2025 reached CNY 2,146,216,262.92, compared to CNY 793,134,205.47 in 2024, reflecting an increase of approximately 171.5%[19] - Operating profit for the first three quarters of 2025 was CNY 2,522,594,956.81, significantly higher than CNY 919,432,930.61 in the previous year, marking an increase of around 174.3%[19] - The net profit attributable to the parent company shareholders for the first three quarters of 2025 is CNY 2,152,182,184.52, compared to CNY 803,855,815.93 in the same period of 2024, representing a significant increase[20] - The total comprehensive income for the first three quarters of 2025 is CNY 2,145,311,321.48, up from CNY 792,454,029.76 in 2024[20] - Basic and diluted earnings per share for the first three quarters of 2025 are both CNY 2.80, compared to CNY 1.04 in 2024, indicating a strong performance improvement[20] Cash Flow - The cash flow generated from operating activities amounted to CNY 102,588,569.58, a significant increase of 727.70% year-on-year[4] - The net cash flow from operating activities increased by 727.70% for the current reporting period, mainly due to a rise in cash received from sales of goods and services[10] - Cash inflows from operating activities for the first three quarters of 2025 amount to CNY 3,640,002,364.59, down from CNY 6,200,789,712.62 in 2024[21] - The net cash flow from operating activities for the first three quarters of 2025 is CNY 590,329,947.27, slightly up from CNY 567,609,005.34 in 2024[21] - Cash outflows from investing activities for the first three quarters of 2025 total CNY 5,010,758,565.34, compared to CNY 1,391,606,362.08 in 2024, indicating increased investment activity[22] - The net cash flow from investing activities for the first three quarters of 2025 is -CNY 1,506,491,600.39, worsening from -CNY 1,175,618,836.51 in 2024[22] - The net cash flow from financing activities for the first three quarters of 2025 is -CNY 979,528,249.55, compared to -CNY 31,519,702.29 in 2024, reflecting a significant increase in cash outflows[22] - The ending cash and cash equivalents balance as of the end of the third quarter of 2025 is CNY 1,048,684,858.24, down from CNY 1,357,743,974.78 in 2024[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 11,585,156,807.98, representing a 7.58% increase from the end of the previous year[5] - Total assets as of September 30, 2025, were CNY 11,585,156,807.98, compared to CNY 10,768,625,044.29 at the end of 2024, reflecting an increase of about 7.6%[15] - Total liabilities decreased to CNY 2,561,059,550.26 as of September 30, 2025, from CNY 2,918,688,717.32 at the end of 2024, a decline of approximately 12.3%[16] - Shareholders' equity attributable to the company was CNY 9,009,343,064.30, up 14.86% from the previous year-end[5] - Shareholders' equity increased to CNY 9,024,097,257.72 as of September 30, 2025, compared to CNY 7,849,936,326.97 at the end of 2024, representing an increase of about 14.9%[16] Product Sales - The sales revenue of the main product, Su Xiao Xin Xin Wan, was CNY 1.716 billion, up 13.34% year-on-year[6] - The sales revenue of Qing Yan Di Wan reached CNY 376 million, marking a year-on-year growth of 38.61%[6] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 58,613[12] - The largest shareholder, Tianjin Pharmaceutical Group Co., Ltd., holds 331,120,528 shares, accounting for 42.997% of total shares[12] Accounting and Reporting Changes - The company plans to divest its wholly-owned subsidiary Tianjin Zhongxin Pharmaceutical Co., Ltd., which will impact revenue recognition in future reports[6] - Operating revenue for the current reporting period decreased by 38.08%, primarily due to changes in the scope of consolidation, as Tianjin Zhongxin Pharmaceutical Co., Ltd. is no longer included in the data[10] - The company will not apply new accounting standards starting from 2025, as stated in the announcement[23]